Biogen Inc. (BIIB) shares soared 5.3% in the last trading session to close at $253.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Key TakeawaysBiogen shares rose 5% today after BofA raised its price target to $244 from $219 and kept a Neutral rating. BofA’s new target is close to the $247 consensus target, which has climbed 43% ...

TD Cowen raised its Biogen target from USD 225.00 to USD 250.00 on October 21, 2026. Its adjusted earnings per share estimate ...

JPMorgan analyst Chris Schott raises Biogen (BIIB) price target to $300 from $210, citing felzartamab and litifilimab ...

Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent ...

Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts. Read more on BIIB stock ...

Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimer’s revenue growth, and key risk/reward ...

JPMorgan highlighted litifilimab’s development for cutaneous lupus erythematosus, a condition with no currently approved ...

Biogen will release data from clinical trials for a few of its investigational treatments over the next few months, which should boost its shares, per JPMorgan.

The company has made several acquisitions since 2022 to balance a portfolio that had become too focused on high-risk neuroscience programs. Ten Phase 3 studies will soon reveal whether the strategy ...

Biogen reported quarterly sales of $2.5 billion, beating consensus with 3% growth from last year. (Biogen) As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady ...

Biogen Inc. (ISIN US09062X1037) remains defined by JPMorgan's October 12, 2026 upgrade from Neutral to Overweight and its ...